Citations

Clear

4847 citation(s) found for "Yu, Eric".

EMBR-03. PINEOBLASTOMA: A POOLED OUTCOME STUDY OF NORTH AMERICAN AND AUSTRALIAN THERAPEUTIC DATA
Huang, Jie , Li, Bryan , Gajjar, Amar , Endersby, Raelene , Wells, Olivia, Wray, Alison, Raleigh, David R. , Stoller, Schuyler , Mueller, Sabine , Bandopadhayay, Pratiti , Fouladi, Maryam , Onar, Arzu, Gottardo, Nicholas G. , Onar‐Thomas, Arzu , Hansford, Jordan R. , Dodgshun, Andrew , Hwang, Eugene , Leary, Sarah , Hoff, Katja von , Kotecha, Rishi S. , Schild, Steven E. , Bouffet, Éric , Huang, Annie

Mayo Clinic

Neuro-Oncology | June 1, 2021 | Volume: 23 | Issue: Supplement_1 | Pages: i6-i6

10.1093/neuonc/noab090.021 Get It

Abstract Background Pineoblastoma (PB) is a rare embryonal brain tumour most often diagnosed in young children. To date, no clinical trials have been conducted specific to pediatric PB. Collaborative studies performed over the past 30 years have included PB in studies accruing for other embryonal tumours, primarily medulloblastoma (MB), but also including the entity formerly known as CNS-PNET and atypical teratoid rhabdoid tumors. Each of these studies have included only a small number of children with PB, making clinical features difficult to interpret and determinants of outcome difficult to ascertain. Patients and Methods Published centrally reviewed series with sufficient treatment and outcome data from North American and Australian cases were pooled. To investigate associations between variables, Fisher’s exact and Wilcoxon-Mann-Whitney tests, and Spearman correlations were used as appropriate. Kaplan-Meier plots, log-rank tests, and Cox proportional hazards models were used in survival analysis. Results We describe a 30-year review of the reported clinical features of PB and a pooled centrally reviewed, cohort analysis of cases (n=178) from the Children’s Oncology Group (COG) (n=82) groups and several published, centrally reviewed institutional series (n=96). We find young children <3 years of age have a dramatically poorer outlook compared to older children (5-year OS 16.2% +/- 5.3% vs 67.3% +/- 5%) confirming new and novel approaches are needed in future clinical trials for this at risk group. Interestingly, male gender was predictive of worse outcome possibly suggestive of gender specific subgroup risks that needs validation in future studies. Assessment of radiation therapy is not possible as the vast majority of children under age three did not receive any form of radiation therapy. Conclusion Given the relative scarcity of this tumor and the emerging data on subgroups of pineoblastoma, prospective, collaborative international studies will be vital to improving the long-term survival of these patients.
Prognostic and Predictive Impact of Primary Tumor Sidedness for Previously Untreated Advanced Colorectal Cancer
Yin, Jun , Cohen, Romain , Jin, Zhaohui , Liu, Heshan , Pederson, Levi , Adams, Richard , Maughan, Tim , Punt, Cornelis J.A. , Koopman, Miriam , Seymour, Michel , Bokemeyer, Carsten , Heinemann, Volker , Chibaudel, Benoist , Gramont, Aimery de , Shi, Qian , Lenz, Heinz‐Josef , Maughan, Timothy S , Koopman, Miriam , Falcone, Alfredo , Seymour, Matthew T , Bokemeyer, Carsten , Kaplan, Richard , Heinemann, Volker , Zalcberg, John , André, Thierry , De Gramont, Aimery , Shi, Qian , Lenz, Heinz-Josef , Adams, Richard , Jin, Zhaohui , Chibaudel, Benoist , Cohen, Romain , Grothey, Axel , Venook, Alan P. , Cutsem, Eric Van , Falcone, Alfredo , Tebbutt, Niall C. , Díaz‐Rubio, Eduardo , Kaplan, Richard , Yoshino, Takayuki , Zalcberg, John , André, Thierry

Mayo Clinic

JNCI: Journal of the National Cancer Institute | May 30, 2021 | Volume: 113 | Issue: 12 | Pages: 1705-1713

10.1093/jnci/djab112 | PMID 34061178 Get It

Abstract Background Unplanned subgroup analyses from several studies have suggested primary tumor sidedness (PTS) as a potential prognostic and predictive parameter in metastatic colorectal cancer (mCRC). We aimed to investigate the impact of PTS on outcomes of mCRC patients. Methods PTS data of 9277 mCRC patients from 12 first-line randomized trials in the ARCAD database were pooled. Overall survival (OS) and progression-free survival (PFS) were assessed using Kaplan-Meier and Cox models adjusting for age, sex, performance status, prior radiation/chemotherapy, and stratified by treatment arm. Predictive value was tested by interaction term between PTS and treatment (cetuximab plus chemotherapy vs chemotherapy alone). All statistical tests were 2-sided. Results Compared with right-sided metastatic colorectal cancer patients (n = 2421, 26.1%), left-sided metastatic colorectal cancer patients (n = 6856, 73.9%) had better OS (median = 21.6 vs 15.9 months; adjusted hazard ratio [HRadj] = 0.71, 95% confidence interval [CI] = 0.67 to 0.76; P < .001) and PFS (median = 8.6 vs 7.5 months; HRadj = 0.80, 95% CI = 0.75 to 0.84; P < .001). Interaction between PTS and KRAS mutation was statistically significant (Pinteraction < .001); left-sidedness was associated with better prognosis among KRAS wild-type (WT) (OS HRadj = 0.59, 95% CI = 0.53 to 0.66; PFS HRadj =0.68, 95% CI = 0.61 to 0.75) but not among KRAS mutated tumors. Among KRAS-WT tumors, survival benefit from anti-EGFR was confirmed for left-sidedness (OS HRadj = 0.85, 95% CI = 0.75 to 0.97; P = .01; PFS HRadj = 0.77, 95% CI = 0.67 to 0.88; P < .001) but not for right-sidedness. Conclusions The prognostic value of PTS is restricted to the KRAS-WT population. PTS is predictive of anti-EGFR efficacy, with a statistically significant improvement of survival for left-sidedness mCRC patients. These results suggest treatment choice in mCRC should be based on both PTS and KRAS status.
Feasibility of capturing real-world data from health information technology systems at multiple centers to assess cardiac ablation device outcomes: A fit-for-purpose informatics analysis report
Jiang, Guoqian , Dhruva, Sanket S. , Chen, Jiajing , Doshi, Amit, Zhang, Shumin , Young, H. P. , Ervin, Keondae, Shah, Nilay D. , Patrick Young, H , Drozda, Joseph P. , Schulz, Wade L. , Noseworthy, Peter A. , Yu, Yue , Brandt, Eric, Ross, Joseph S. , COPLAN, PAUL M.

Mayo Clinic

Journal of the American Medical Informatics Association | May 29, 2021 | Volume: 28 | Issue: 10 | Pages: 2241-2250

10.1093/jamia/ocab117 | PMID 34313748 Get It

Abstract Objective The study sought to conduct an informatics analysis on the National Evaluation System for Health Technology Coordinating Center test case of cardiac ablation catheters and to demonstrate the role of informatics approaches in the feasibility assessment of capturing real-world data using unique device identifiers (UDIs) that are fit for purpose for label extensions for 2 cardiac ablation catheters from the electronic health records and other health information technology systems in a multicenter evaluation. Materials and Methods We focused on data capture and transformation and data quality maturity model specified in the National Evaluation System for Health Technology Coordinating Center data quality framework. The informatics analysis included 4 elements: the use of UDIs for identifying device exposure data, the use of standardized codes for defining computable phenotypes, the use of natural language processing for capturing unstructured data elements from clinical data systems, and the use of common data models for standardizing data collection and analyses. Results We found that, with the UDI implementation at 3 health systems, the target device exposure data could be effectively identified, particularly for brand-specific devices. Computable phenotypes for study outcomes could be defined using codes; however, ablation registries, natural language processing tools, and chart reviews were required for validating data quality of the phenotypes. The common data model implementation status varied across sites. The maturity level of the key informatics technologies was highly aligned with the data quality maturity model. Conclusions We demonstrated that the informatics approaches can be feasibly used to capture safety and effectiveness outcomes in real-world data for use in medical device studies supporting label extensions.
Closure of Scalp and Forehead Defects Using External Tissue Expander
O’Reilly, Ashley G., Schmitt, William R., Roenigk, Randall K., Moore, Eric J. , Price, Daniel L.

Mayo Clinic

Archives of Facial Plastic Surgery | May 28, 2021 | Volume: 14 | Issue: 6 | Pages: 419-422

10.1001/archfaci.2012.662 Get It

Tegaserod for Irritable Bowel Syndrome With Constipation in Women Younger Than 65 Years Without Cardiovascular Disease: Pooled Analyses of 4 Controlled Trials
Shah, Eric D. , Lacy, Brian E. , Chey, William D. , Shah, Eric D , Chang, Lin , Brenner, Darren M.

Mayo Clinic

American Journal of Gastroenterology | May 28, 2021 | Volume: 116 | Issue: 8 | Pages: 1601-1611

10.14309/ajg.0000000000001313 | PMID 34047303 Get It

INTRODUCTION: Tegaserod was the first US Food and Drug Administration–approved drug for irritable bowel syndrome with constipation (IBS-C) in women and was recently reapproved for use. Recognizing that clinical trials were performed almost 20 years ago, we performed an integrated analysis on patient-reported outcomes relevant to current practice including previously unpublished data. METHODS: Data from 4 12-week, randomized, placebo-controlled trials evaluating tegaserod 6 mg b.i.d. in patients with IBS-C were pooled. We analyzed 2 groups: all women (overall population) and women younger than 65 years without a history of cardiovascular ischemic events (indicated population). The primary end point was subjective global assessment of IBS-C symptom relief. Responders rated themselves as “considerably” or “completely” relieved ≥50% of the time or at least “somewhat relieved” 100% of the time over the last 4 weeks. RESULTS: The overall and indicated populations included 2,939 (tegaserod [n = 1,478]; placebo [n = 1,461]) and 2,752 (tegaserod [n = 1,386]; placebo [n = 1,366]) participants, respectively. The pooled odds ratios (95% confidence interval) for clinical response during the last 4 weeks in the overall and indicated populations with tegaserod were 1.37 (1.18, 1.59; P < 0.001) and 1.38 (1.18, 1.61; P < 0.001). In the overall and indicated populations, clinical response rates for tegaserod during the last 4 weeks were 43.3% and 44.1% versus 35.9% and 36.5% with placebo ( P < 0.001). Adverse events were similar between groups. No significant cardiovascular events related to tegaserod were observed in patients with ≤1 cardiac risk factor. DISCUSSION: Tegaserod 6 mg b.i.d. reduced IBS-C symptoms in overall and US Food and Drug Administration–indicated populations (women aged <65 years with no history of cardiovascular ischemic events).
DOP84 Early treatment responses within 14 days of intravenous vedolizumab induction therapy for Crohn’s Disease: Post hoc analysis of patient-reported outcomes from the VISIBLE 2 study
D’Haens, Geert , Baert, Filip , Sandborn, William J. , Dornic, Quentin, Lindner, Dirk , Kisfalvi, Krisztina, Marins, Eric, Danese, Silvio , Kobayashi, Taku , Loftus, Edward V. , Lindner, D, Marins, E G, Vermeire, Séverine

Mayo Clinic

Journal of Crohn's and Colitis | May 28, 2021 | Volume: 15 | Issue: Supplement_1 | Pages: S115-S116

10.1093/ecco-jcc/jjab073.123 Get It

Abstract Background Vedolizumab (VDZ), an anti-a4β7 integrin antibody that selectively blocks lymphocyte trafficking to the gut, is approved for the treatment of adult patients with moderate-to-severe Crohn’s disease (CD). This post hoc analysis of data from the VISIBLE 2 trial evaluated early patient-reported outcomes assessed within the first 14 days of VDZ induction. Methods VISIBLE 2 (NCT02611817; EudraCT 2015-000481-58) was a phase 3, multicentre, placebo-controlled study, evaluating the efficacy and safety of subcutaneous VDZ for maintenance treatment in patients with moderately to severely active CD. Efficacy was assessed based on CD Activity Index (CDAI). Patients received induction treatment with intravenous (IV) VDZ 300 mg open-label at Weeks 0 and 2. For this analysis, responses to VDZ were assessed using CDAI sub-scores for patient-reported abdominal pain (AP) and stool frequency (SF) collected daily via electronic diary in the first 14 days of VDZ treatment (Day 1 to 15) in all patients receiving ≥1 VDZ dose at induction. Descriptive statistics were used. Results The analysis included 611 patients (mean [SD] age 37.6 [13.4] years; CD duration 9.0 [8.1] years); 323 (53%) were male; 228 (37%) had severe disease (CDAI &gt;330) at baseline; and 350 (57%) were anti-TNF-experienced. In the first 14 days of VDZ IV induction, the rate of patients with daily SF≤3 increased from 30% at baseline (Day 1) to 47.7% on Day 15. Increases were similar in both anti-TNF-naïve vs. anti-TNF-experienced patients and in patients with severe vs. moderate disease (Figure 1). Mean baseline SF was reduced from 6.4 to 5.0 at Day 15 in patients with severe disease and from 4.3 to 3.5 in patients with moderate disease. Overall, the proportion of patients rating AP as severe/moderate declined from baseline to Day 15 of induction (from 14.6% to 8.2% for severe AP and from 60.7% to 40.6% for moderate AP). Similar Day 1-to-15 reductions were reported in both anti-TNF-naïve (severe AP: 14.2% to 9.2%; moderate AP: 62.6% to 44.6%) and anti-TNF-experienced patients (severe AP: 14.8% to 7.4%; moderate AP: 59.3% to 37.7%), respectively. Although a minority of patients (6.3%) in the sub-group with moderate AP at baseline had worse pain at Day 15, there were early improvements in AP ratings for most patients reporting severe or moderate AP at baseline (Figure 2). Conclusion This post hoc analysis of daily patient-reported SF and AP in the VISIBLE 2 CD study indicates an early onset of response to VDZ IV induction within the first 14 days of treatment.
Comparison of the Prevalence of Pathogenic Variants in Cancer Susceptibility Genes in Black Women and Non-Hispanic White Women With Breast Cancer in the United States
Goldgar, David E. , Nathanson, Katherine L. , Haiman, Christopher A. , Chen, Chen , Chen, Fei , Kurian, Allison W. , Chen, C , Nathanson, Katherine L , Kurian, Allison W , Chen, Fei , Domchek, Susan M. , Yao, Song , Chen, Fei , Hu, Chunling , Hart, Steven N. , Ambrosone, Christine B. , Couch, Fergus J. , Polley, Eric C. , Palmer, Julie R.

Mayo Clinic

JAMA Oncology | May 27, 2021 | Volume: 7 | Issue: 7 | Pages: 1045

10.1001/jamaoncol.2021.1492 | PMID 34042955 Get It

TSPEAR variants are primarily associated with ectodermal dysplasia and tooth agenesis but not hearing loss: A novel cohort study
Bowles, Bradley , Ferrer, Alejandro , Nishimura, Carla, Rey, Tristan, Leheup, Bruno, Sullivan, Jennifer A. , Schoch, Kelly, Stong, Nicholas , Agolini, Emanuele , Cocciadiferro, Dario , Williams, Abigail , Cummings, Alex, Genovese, Silvia , Roadhouse, Chelsea, Network, Undiagnosed Diseases, Wentzensen, Ingrid M. , Li, Chumei , Babovic‐Vuksanovic, Dusica , Lanpher, Brendan C. , Dentici, Maria Lisa , Hamm, J. Austin, Shashi, Vandana , Gérard, Bénédicte , Bloch‐Zupan, Agnès , Smith, Richard J. , Klee, Eric W. , Oglesbee, Devin , McCauley, Jacob L. , Nelson, Stanley F. , Azamian, Mahshid S. , Martínez-Agosto, Julián A. , Chang, Ta Chen , Blue, Elizabeth , Woods, Jeremy D. , Baldridge, Dustin , Pinto E Vairo, Filippo, Sullivan, Jennifer , Agolini, Emanuele , Loddo, Sara , Genovese, Silvia , Li, Chumei , Babovic-Vuksanovic, Dusica, Dentici, Maria Lisa , Ankala, Arun , Radio, Francesca Clementina , Bloch-Zupan, Agnes , Oglesbee, Devin , Baldridge, Dustin , Stong, Nicholas , Ferrer, Alejandro , McCauley, Jacob L , Vairo, Filippo Pinto e , McWalter, Kirsty , Network, Undiagnosed Diseases, Dallapiccola, Bruno , Radio, Francesca Clementina

Mayo Clinic

American Journal of Medical Genetics Part A | May 27, 2021 | Volume: 185 | Issue: 8 | Pages: 2417-2433

10.1002/ajmg.a.62347 | PMID 34042254 Get It

AbstractBiallelic loss‐of‐function variants in the thrombospondin‐type laminin G domain and epilepsy‐associated repeats (TSPEAR) gene have recently been associated with ectodermal dysplasia and hearing loss. The first reports describing a TSPEAR disease association identified this gene is a cause of nonsyndromic hearing loss, but subsequent reports involving additional affected families have questioned this evidence and suggested a stronger association with ectodermal dysplasia. To clarify genotype–phenotype associations for TSPEAR variants, we characterized 13 individuals with biallelic TSPEAR variants. Individuals underwent either exome sequencing or panel‐based genetic testing. Nearly all of these newly reported individuals (11/13) have phenotypes that include tooth agenesis or ectodermal dysplasia, while three newly reported individuals have hearing loss. Of the individuals displaying hearing loss, all have additional variants in other hearing‐loss‐associated genes, specifically TMPRSS3, GJB2, and GJB6, that present competing candidates for their hearing loss phenotype. When presented alongside previous reports, the overall evidence supports the association of TSPEAR variants with ectodermal dysplasia and tooth agenesis features but creates significant doubt as to whether TSPEAR variants are a monogenic cause of hearing loss. Further functional evidence is needed to evaluate this phenotypic association.
CSNK2B: A broad spectrum of neurodevelopmental disability and epilepsy severity
Ernst, Michelle, Baugh, Evan H., Thomas‐Wilson, Amanda , Bier, Louise , Lippa, Natalie , Stong, Nicholas , Mulhern, Maureen , Kushary, Sulagna , Akman, Cigdem I. , Heinzen, Erin L. , Yeh, Raymond, He, Weimin , Hanchard, Neil A. , Burrage, Lindsay C. , Leduc, Magalie S. , Chong, Josephine S. C., Bend, Renee, Lyons, Michael J. , Lee, Jennifer A. , Suwannarat, Pim, Brilstra, Eva H. , Simon, Marleen, Binsbergen, Ellen van , Groepper, Daniel , Fleischer, Julie , Keren, Boris , Mignot, Cyril , Mathieu, Sophie , Mancini, Grazia M.S. , Madan‐Khetarpal, Suneeta, Infante, Elena , Bluvstein, Judith , Seeley, Andrea , Bachman, Kristine , Klee, Eric W. , Schultz‐Rogers, Laura , Hasadsri, Linda , Barnett, Sarah , Ellingson, Marissa S. , Ferber, Matthew J. , Ramsey, Keri , Rauch, Anita , Joset, Pascal , Steindl, Katharina , Sheehan, Theodore , Vasquez, Alejandra , Ruivenkamp, Claudia , White, Susan M. , Monaghan, Kristin G. , Goldstein, David B. , Sands, Tristan T. , Aggarwal, Vimla S. , Ernst, Michelle E , Schultz-Rogers, Laura E, Sheehan, Theodore , Poduri, Annapurna , Sands, Tristan T , Rauch, Anita , Burrage, Lindsay C , Stong, Nicholas , Yeh, Raymond, Koopmans, Marion , Nava, Caroline , Narayanan, Vinodh , Pais, Lynn

Mayo Clinic

Epilepsia | May 27, 2021 | Volume: 62 | Issue: 7 | Pages: No page available

10.1111/epi.16931 | PMID 34041744 Get It

AbstractCSNK2B has recently been implicated as a disease gene for neurodevelopmental disability (NDD) and epilepsy. Information about developmental outcomes has been limited by the young age and short follow‐up for many of the previously reported cases, and further delineation of the spectrum of associated phenotypes is needed. We present 25 new patients with variants in CSNK2B and refine the associated NDD and epilepsy phenotypes. CSNK2B variants were identified by research or clinical exome sequencing, and investigators from different centers were connected via GeneMatcher. Most individuals had developmental delay and generalized epilepsy with onset in the first 2 years. However, we found a broad spectrum of phenotypic severity, ranging from early normal development with pharmacoresponsive seizures to profound intellectual disability with intractable epilepsy and recurrent refractory status epilepticus. These findings suggest that CSNK2B should be considered in the diagnostic evaluation of patients with a broad range of NDD with treatable or intractable seizures.
Recommendations for Statistical Reporting in Cardiovascular Medicine: A Special Report From the American Heart Association
Althouse, Andrew D. , Below, Jennifer E , Claggett, Brian , Cox, Nancy J. , Lemos, James A. de , Deo, Rahul C. , Duval, Sue , Hachamovitch, Rory , Kaul, Sanjay , Keith, Scott W. , Teixeira‐Pinto, Armando , Roger, Véronique L. , Below, Jennifer E , Secemsky, Eric A.

Mayo Clinic

Circulation | May 25, 2021 | Volume: 144 | Issue: 4 | Pages: No page available

10.1161/circulationaha.121.055393 | PMID 34032474 Get It

Statistical analyses are a crucial component of the biomedical research process and are necessary to draw inferences from biomedical research data. The application of sound statistical methodology is a prerequisite for publication in the American Heart Association (AHA) journal portfolio. The objective of this document is to summarize key aspects of statistical reporting that might be most relevant to the authors, reviewers, and readership of AHA journals. The AHA Scientific Publication Committee convened a task force to inventory existing statistical standards for publication in biomedical journals and to identify approaches suitable for the AHA journal portfolio. The experts on the task force were selected by the AHA Scientific Publication Committee, who identified 12 key topics that serve as the section headers for this document. For each topic, the members of the writing group identified relevant references and evaluated them as a resource to make the standards summarized herein. Each section was independently reviewed by an expert reviewer who was not part of the task force. Expert reviewers were also permitted to comment on other sections if they chose. Differences of opinion were adjudicated by consensus. The standards presented in this report are intended to serve as a guide for high-quality reporting of statistical analyses methods and results.